Log in

NASDAQ:ALIMAlimera Sciences Stock Price, Forecast & News

$5.03
-0.04 (-0.79 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.90
Now: $5.03
$5.25
50-Day Range
$4.01
MA: $5.15
$5.81
52-Week Range
$2.86
Now: $5.03
$15.45
Volume10,875 shs
Average Volume9,565 shs
Market Capitalization$25.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Read More
Alimera Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.94 million
Book Value($7.10) per share

Profitability

Net Income$-10,440,000.00

Miscellaneous

Employees124
Market Cap$25.30 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

How has Alimera Sciences' stock been impacted by COVID-19 (Coronavirus)?

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALIM shares have decreased by 4.0% and is now trading at $5.0290. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alimera Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alimera Sciences.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Alimera Sciences.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) released its quarterly earnings results on Wednesday, April, 29th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.19. The biopharmaceutical company had revenue of $14.54 million for the quarter, compared to analysts' expectations of $14.04 million. View Alimera Sciences' earnings history.

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Alimera Sciences shares reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences updated its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14 million, compared to the consensus revenue estimate of $12.87 million.

What price target have analysts set for ALIM?

2 brokers have issued 1-year price targets for Alimera Sciences' stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate Alimera Sciences' stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 188.3% from the stock's current price. View analysts' price targets for Alimera Sciences.

Has Alimera Sciences been receiving favorable news coverage?

Media coverage about ALIM stock has been trending somewhat negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alimera Sciences earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAlimera Sciences.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,500 shares, a drop of 37.5% from the April 30th total of 4,000 shares. Based on an average daily trading volume, of 32,100 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company's shares are short sold. View Alimera Sciences' Current Options Chain.

Who are some of Alimera Sciences' key competitors?

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), Agenus (AGEN), Opko Health (OPK), Advanced Micro Devices (AMD), Catalyst Pharmaceuticals (CPRX), CorMedix (CRMD) and Novavax (NVAX).

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the following people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
  • Dr. Kenneth Green, Consultant (Age 61)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
  • Mr. J. Philip Jones, Chief Financial Officer (Age 55)

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $5.03.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $25.30 million and generates $53.94 million in revenue each year. The biopharmaceutical company earns $-10,440,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is www.alimerasciences.com.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.